Kuros Biosciences Reports Significant Sales Growth and Exceeds Cash Flow Breakeven

Kuros Biosciences AG has announced a notable 149% rise in direct MagnetOs sales, reaching CHF 50.6 million in the first nine months of 2024. This is a significant increase compared to CHF 20.4 million during the same period in 2023. The total sales for the Kuros Medical Devices segment reached CHF 51.1 million, up from CHF 21.3 million the previous year.

The company's Medical Devices segment reported an EBITDA of CHF 13.3 million, with an EBITDA margin of 26%, reflecting profitable operations. Kuros also reported cash and cash equivalents of CHF 15.8 million, up from CHF 14.3 million in June, and exceeded its cash flow breakeven point for the first time.

Kuros continues to invest in its Project Fusion and is expanding its market presence internationally, with new distributors in Australia and the UK, as well as commercial clearances in the UAE and Qatar.